At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding real-world characteristics and treatment by disease volume among patients with metastatic castration-sensitive prostate cancer. Dr. Freedland shares more regarding the complexities of treatment decisions in prostate cancer, barriers to care, and the research that he and his team are conducting to optimize treatment utilization based on disease characteristics.
A survey conducted by i3 Health at the Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 18 to 22, 2023, in Tucson, Arizona, has provided valuable insights into urologists' preferred formats and desired topics of continuing medical education (CME) activities, as well as the most important factors they consider when choosing such activities. Additionally, survey participants were asked an additional set of questions regarding their confidence and comf...
For patients with testicular cancer, planning is necessary to ensure that patients feel prepared regarding the implications of their disease in the years after they finish treatment. In this interview in honor of Testicular Cancer Awareness Month, Dr. Katie Murray, Assistant Professor at the University of Missouri Department of Surgery-Urology, shares advice for members of the cancer care team on how to counsel their patients on planning for life after testicular cancer.
For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the management of individual patients with testicular cancer, with the goal of minimizing toxicity and achieving the best possible outcomes for treatment and surgery. This interview has been conducted in partnership with the American Urological Association, a premier urologic ...
This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be considered when selecting treatment options—including surgery, chemotherapy, radiation, or surveillance—for patients with testicular cancer, the future of recent advances such as cancer detection with microRNA, and the importance of taking a multidisciplinary approach to ensure the best possible outcomes for patients with this disease.
Oncology Data Advisor™ · Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be considered when selecting treatment options—including surgery, chemotherapy, radiation, or surveillance—for patients with testicular cancer, the future of...
This interview in honor of Testicular Cancer Awareness Month features Dr. Andrew Winer, Chief of Urology at Kings County Hospital in New York. Dr. Winer discusses the ongoing research regarding new approaches for testicular cancer surgery, strategies to address disparities in health care access for underserved populations, and the importance of taking a multidisciplinary approach to achieve the best possible outcomes for patients with testicular cancer.
In order to accurately recognize the continuing medical education (CME) needs and preferences of urology/oncology health care providers, i3 Health administered a survey to participants at the 66th Society of Government Service Urologists Kimbrough Urological Seminar. The results obtained from the survey will be used by i3 Health in the planning and implementation of CME-approved activities. Of the 22 participants who completed the survey, 72.7% were urologists, 18.2% were residents, 4.5% were fe...
Over the past few years, the treatment options for castration-resistant prostate cancer (CRPC) have increased to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metastasis-targeted agents. Due to an absence of large prospective trials, clinical decision making needs to be based on many different factors, including optimal treatment sequences and combinations, patient health status (eg, asymptomatic or symptomatic), rate of disease progression...